I think this is a very realistic view, it is nice to be optimistic but in reality what you describe is easier to believe. However, i think of cytodyn's situation in a way as the same feeling you get went looking at a mountain you must climb. at the base, looking up, it is an impossible looking task and the further you get, the more un- motivating it gets because the effort expands faster than the progress you make. When you get to the top, you look around and strangely all the thoughts you had of how impossible this climb is while doing it fade away and it seems like it always was an achievable task. It is just perspective.

There is nothing stopping a PR that cytodyn has a major partner in NASH. It is optimistic but there is no lack of data showing Leronlimab is doing what no other drug has done in phase 2.

Cytodyn may have already compiled the extra data from the mTNBC trial and we are deep into the 60 day review for BTD. Maybe we applied for a different cancer BTD using the basket trial?

The BLA may have already been sent tot he FDA and we might get the first knowledge of it when the FDA gives a PUFTA date.

Cytodyn is not just sitting around waiting fo rhte phone to ring. there are many VC firms that only watch biotechs like cytodyn and jump in because they know a BP is going to want leronlimab very badly very soon. BP knows about leronlimab and they know the FDA, they see the opportunity - just have not acted yet.

another clear thing is, Cytodyn is not selling this short. they know what the have and so do we. We have to just play to the audience when it benefits us. keep in mind, all the active employees and BOD have other careers and are already wealthy, they are not in a desperate situation. the "Nader's in it for the paycheck" is old now.